Article Text

Download PDFPDF
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al
  1. Milena Gianfrancesco1,
  2. Kimme L Hyrich2,
  3. Jinoos Yazdany1,
  4. Pedro M Machado3,4,
  5. Philip C Robinson5,6
  1. 1 Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA
  2. 2 Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK
  3. 3 MRC Centre for Neuromuscular Diseases, University College London, London, UK
  4. 4 Rheumatology, University College London Centre for Rheumatology, London, UK
  5. 5 Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia
  6. 6 Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia
  1. Correspondence to Dr Philip C Robinson, Faculty of Medicine, The University of Queensland, Herston, QLD 4072, Australia; philip.robinson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Khan and colleagues, Dr Ansarin and colleagues and Dr Andreica and colleagues for their correspondence in relation to our paper.1–4 The reported experience of Dr Khan and colleagues2 in using anti-interleukin (IL)-6 therapy in the treatment of COVID-19 is interesting, and although there has been much positive observational data reported on the value of anti-IL-6 therapy in COVID-19, including in this journal,5 preliminary reports from two randomised trials have not shown benefit.6 7 When further data are published on anti-IL-6 therapy in treating COVID-19, we can hopefully understand better if this therapy will have a place. Detailed cytokine analysis of 1484 patients with COVID-19 found that IL-6 and tumour necrosis factor (TNF) were independent and significant predictors of poor outcome.8 Therefore, TNF also …

View Full Text


  • Handling editor Josef S Smolen

  • Twitter @pedrommcmachado, @philipcrobinson

  • Contributors PCR drafted the correspondence. All authors edited and provided approval of the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MG reports grants from National Institutes of Health, NIAMS, outside the submitted work; KLH reports she has received speaker’s fees from Abbvie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript. KLH is also supported by the NIHR Manchester Biomedical Research Centre; JY reports personal fees from Astra Zeneca, personal fees from Eli Lilly, grants from Pfizer, outside the submitted work; PMM reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from UCB, outside the submitted work. PCR reports personal fees from Abbvie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, UCB Pharma and non-financial support from BMS and Roche, outside the submitted work.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles